preview

Case Study On Dengvaxia

Good Essays

1. Problem statement in your own words Sanofi Pasteur, a pharmaceutical company based in France made a business deal with the previous Philippines’ Department of Health (DOH) Secretary in 2015 to provide dengue vaccine called Dengvaxia (Caplan & Folkers, 2017, para. 3). However, Dengvaxia led to the deaths of innocent children (Caliwan, 2018, para. 1). To begin, Sanofi and the DOH Secretary was in cahoots in misrepresenting Dengvaxia (ThinkingPinoy, 2017, para. 5). Prior to the inoculations, the World Health Organization (WHO) warned about the adverse effect and the ineffectiveness of Dengvaxia (ThinkingPinoy, 2017, para. 26). Despite of the warnings, the DOH started the massive inoculations in April 4, 2016 (ThinkingPinoy, 2017, para. …show more content…

Alternative 3 – The CEO should fight the case in court and deny allegations concerning Dengvaxia. i. 2 or more advantages  Less cost compared to other alternatives  Standing by the integrity of Dengvaxia  If Sanofi win the case, it will keep the trust of its investors ii. 2 or more disadvantages  WHO has contradicting reports about Dengvaxia  Undermines evidences collected in the autopsies  Likely escalate the problem with the Filipinos  A lengthy battle because more parents are seeking investigations over the death of their children 4. Conclusion and recommendations In summary, Sanofi is in embattlement with the Filipinos over the controversial Dengvaxia. Now, the Sanofi’s CEO is facing a complex problem which originated from “failure of ethics and corporate governance” (Schermerhorn & Bachrach, 2015, p.18). Nevertheless, I recommend that Sanofi’s CEO should consider the Alternative 2 listed above as a solution, because Dengvaxia is the root cause of the problems. In this complex situation, the appropriate solution is controlling by killing the roots from growing. As CEO there is accountability, but, the CEO must consider the future of the business as well. The alternative 2 opens for “retrenchment strategy” and opens for a possible resurrection of the business as …show more content…

& Folkers, K.M. (2017, December 7). A Clinical Trial By Any Other Name… [Web log post]. Retrieved from https://cedriccracraft.wordpress.com/2017/12/07/a-clinical-trial-by-any-other-name/ Khatun, R. (2018). Philippine lawyer sue Sanofi over dengue vaccine. Retrieved from https://business.medicaldialogues.in/philippine-lawyers-sue-sanofi-dengue-vaccine/ Latin American Herald Tribune. (2018). Philippines Links 3 Children’s Death to Sanofi Pasteur Dengue Vaccine. Retrieved from http://www.laht.com/article.asp?ArticleId=2450201&CategoryId=13936 Raghavan, P., RAJAGOPAL, D., & ET Bureau. (2017). Sanofi continues to seek clinical trial waiver in India for controversial dengue vaccine. Retrieved from https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sanofi-continues-to-seek-clinical-trial-waiver-in-india-for-controversial-dengue-vaccine/articleshow/61938253.cms Rangan, V. K., Bloom, D. E., Dessain, V., & Billaud, E. (2014). Sanofi Pasteur: The Dengue Vaccine Dilemma. Retrieved from https://www.hbs.edu/faculty/Pages/item.aspx?num=47294 Schermerhorn, J. R., & Bachrach, D. G. (2015). Exploring Management. (5th ed.). Hoboken, NJ: John Wiley & Sons, Inc., p.

Get Access